Latest news for  (OTC:RWBFS) Stock

Novo Nordisk A/S Common Stock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) experienced a notable decline on Thursday. This movement follows a significant announcement from <a href="https://www.benzinga.com/news/24/07/39966690/viking-therapeutics-stock-surges-as-company-advances-weight-loss-drug-to-late-stage-trial-what-inves">competitor Viking Therapeutics Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>).
What To Know: Viking Therapeutics announced the company has advanced its obesity candidate VK2735 into late-stage trials. This <a href="https://www.benzinga.com/news/24/07/39966690/viking-therapeutics-stock-surges-as-company-advances-weight-loss-drug-to-late-stage-trial-what-inves">advancement has intensified competition</a> in the GLP-1 market, which is currently led by Novo Nordisk and Eli Lilly corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>).
Viking Therapeutics&#8217; report of promising results for its obesity drug, showing up to a 15% reduction in body weight over 13 weeks, has pressured Novo Nordisk. This development challenges Novo Nordisk's leading position in the obesity treatment market.
What Else: The options market for Novo Nordisk has shown a predominantly bearish sentiment recently. Out of eight detected trades, 62% were bearish, including three put options totaling $155,555 and five call options amounting to $255,360.
Novo Nordisk&#8217;s trading volume reached 1,568,565, with the stock nearing oversold conditions according to RSI indicators. The company's next earnings report is expected in 13 days. 
Analyst Opinions: Cantor Fitzgerald recently downgraded Novo Nordisk to &#8216;Overweight&#8217; but maintained a price target of $160.
NVO Price Action: Novo Nordisk shares were down by 2.88% at $127.86 according to<a href="https://pro.benzinga.com/dashboard"> Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/pro/checkout/benzinga-pro-essential-2024?utm_source=BZprocontent072524&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="1024" height="540" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/25160653/NVO-1024x540.png" alt="" class="wp-image-457886" style="width:425px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/25160653/NVO-1024x540.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/25160653/NVO-300x158.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/25160653/NVO-768x405.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/25160653/NVO.png 1077w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
See Also:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/07/39966014/can-independent-bank-corp-run-higher-on-rising-earnings-estimates">Can Independent Bank Corp. Run Higher on Rising Earnings Estimates?</a></li>
</ul>
Photo via Shutterstock.

News

Health Care

After-Hours Center

Movers

VKTX

Novo Nordisk Shares Decline Amid Competitive Pressure

Guidance

SSNC

SS&C Sees FY24 Revenue $5.7B-$5.86B Vs $6.03B Estimate; Sees Adj. EPS $4.98-$5.22 Vs $5.64 Estimate

DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) reported quarterly earnings of $0.43 per share which beat the analyst consensus estimate of $0.39 by 10.26 percent. The company reported quarterly sales of $1.004 billion which missed the analyst consensus estimate of $1.036 billion by 3.13 percent. This is a 15.23 percent increase over sales of $871.300 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

DXCM

DexCom Q2 2024 Adj EPS $0.43 Beats $0.39 Estimate, Sales $1.004B Miss $1.036B Estimate

Kinsale Cap Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNSL#NYSE">KNSL</a>) reported quarterly earnings of $3.97 per share which beat the analyst consensus estimate of $3.53 by 12.46 percent. The company reported quarterly sales of $384.55 million which beat the analyst consensus estimate of $372.57 million by 3.22 percent. This is a 30.02 percent increase over sales of $295.77 million the same period last year.

KNSL

Kinsale Cap Gr Q2 2024 Adj EPS $3.97 Beats $3.53 Estimate, Sales $384.55M Beat $372.57M Estimate

Data reviewed complies with standards that would be&nbsp;used to evaluate an EU Marketing Authorization Application
PLYMOUTH MEETING, Pa., July 25, 2024 /PRNewswire/ -- INOVIO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>), a biotechnology company focused on developing and commercializing DNA medicines to&nbsp;help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that&nbsp;the European Medicines Agency's Committee for Advanced Therapies (CAT) has certified the quality and non-clinical data for INO-3107, INOVIO's lead candidate&nbsp;for&nbsp;the treatment of Recurrent Respiratory Papillomatosis (RRP). The certification confirms that INOVIO's chemistry, manufacturing and controls (CMC) data and nonclinical results available to date comply with the scientific and technical standards that would be used for evaluating a European Marketing Authorization Application.

Biotech

General

Inovio Receives Advanced Therapy Medicinal Product Certificate From EMA For Quality And Non-Clinical Data For Lead Candidate INO-3107

Universal Logistics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULH#NASDAQ">ULH</a>) reported quarterly earnings of $1.17 per share which beat the analyst consensus estimate of $1.14 by 2.63 percent. The company reported quarterly sales of $462.164 million which beat the analyst consensus estimate of $461.600 million by 0.12 percent. This is a 12.02 percent increase over sales of $412.572 million the same period last year.

Universal Logistics Hldgs Q2 2024 GAAP EPS $1.17 Beats $1.14 Estimate, Sales $462.164M Beat $461.600M Estimate

Wolfe Research analyst Steve Fleishman downgrades NextEra Energy Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEP#NYSE">NEP</a>) from Outperform to Peer Perform.

Downgrades

Analyst Ratings

Wolfe Research Downgrades NextEra Energy Partners to Peer Perform

SS&C Technologies Expects Q3 Adjusted Revenue $1.42B – $1.46B (Est $1.44B), Adj EPS Of $1.21 – $1.27 (Est $1.27)

SS&C Sees Q3 2024 Adj. Revenue $1.42B-$1.46B Vs $1.432B Estimate; Sees Adj. EPS $1.21-$1.27 Vs $1.20 Estimate

Magyar Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGYR#NASDAQ">MGYR</a>) reported quarterly earnings of $0.27 per share. This is a 10 percent decrease over earnings of $0.30 per share from the same period last year.

MGYR

Magyar Bancorp Q3 EPS $0.27 Down From $0.30 YoY

Exponent (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPO#NASDAQ">EXPO</a>) reported quarterly earnings of $0.57 per share which beat the analyst consensus estimate of $0.50 by 14 percent. The company reported quarterly sales of $140.536 million which beat the analyst consensus estimate of $130.827 million by 7.42 percent. This is a 0.22 percent increase over sales of $140.221 million the same period last year.

EXPO

Exponent Q2 2024 GAAP EPS $0.57 Beats $0.50 Estimate, Sales $140.536M Beat $130.827M Estimate

Erie Indemnity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERIE#NASDAQ">ERIE</a>) reported quarterly earnings of $3.13 per share which beat the analyst consensus estimate of $2.55 by 22.75 percent.

ERIE

Erie Indemnity Q2 2024 GAAP EPS $3.13 Beats $2.55 Estimate

COLM

Columbia Sportswear Sees Q4 2024 EPS $3.65-$4.05

The anticipated improvement in demand for&nbsp;Chlor Alkali Products and Vinyls business has been slower to develop than expected earlier this year.
&quot;We currently estimate that Olin&#39;s&nbsp;third quarter&nbsp;2024 adjusted EBITDA will be reduced by approximately&nbsp;$100 million&nbsp;due to incremental costs to restore operations, unabsorbed fixed manufacturing costs, and reduced profit from lost sales associated with the storm. Before considering the effects of Hurricane Beryl, we had anticipated our Chemical businesses&#39;&nbsp;third quarter&nbsp;2024 adjusted EBITDA would have been comparable to&nbsp;second quarter&nbsp;2024. We expect our Winchester business&nbsp;third quarter&nbsp;results to improve from&nbsp;second quarter&nbsp;levels with seasonally stronger commercial ammunition demand and higher military shipments and project revenue.&quot;

Olin Expects H2'2024 Adjusted EBITDA Would Have Been Comparable To H1'2024

Rogers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROG#NYSE">ROG</a>) reported quarterly earnings of $0.69 per share which beat the analyst consensus estimate of $0.60 by 15 percent. The company reported quarterly sales of $214.200 million which missed the analyst consensus estimate of $216.150 million by 0.90 percent. This is a 7.20 percent decrease over sales of $230.821 million the same period last year.

Rogers Q2 2024 Adj EPS $0.69 Beats $0.60 Estimate, Sales $214.200M Miss $216.150M Estimate

Phillips Edison (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PECO#NASDAQ">PECO</a>) reported quarterly earnings of $0.12 per share which missed the analyst consensus estimate of $0.13 by 7.69 percent. This is unchanged from the same period last year. The company reported quarterly sales of $161.51 million which missed the analyst consensus estimate of $162.02 million by 0.31 percent. This is a 6.16 percent increase over sales of $152.14 million the same period last year.

PECO

Phillips Edison Q2 EPS $0.12 Misses $0.13 Estimate, Sales $161.51M Miss $162.02M Estimate

Eastern Bankshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EBC#NASDAQ">EBC</a>) reported quarterly earnings of $0.22 per share which beat the analyst consensus estimate of $0.20 by 10 percent.

Eastern Bankshares Q2 2024 GAAP EPS $0.22 Beats $0.20 Estimate

Hartford Finl Servs Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIG#NYSE">HIG</a>) reported quarterly earnings of $2.50 per share which beat the analyst consensus estimate of $2.24 by 11.61 percent. The company reported quarterly sales of $6.49 billion which missed the analyst consensus estimate of $6.57 billion by 1.30 percent. This is a 7.22 percent increase over sales of $6.05 billion the same period last year.

Hartford Finl Servs Gr Q2 2024 Adj EPS $2.50 Beats $2.24 Estimate, Sales $6.49B Miss $6.57B Estimate

WIIM

Boston Beer Company shares are trading lower after the company reported worse-than-expected Q2 financial results.

KGI Securities analyst Jennifer Liang downgrades Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) from Outperform to Neutral and announces $236 price target.

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments

News

Latest news for (OTC:RWBFS) Stock